Good inquiry, however, a definitive response is absent. It is crucial to consider the karyotyping of bone marrow cells is carried out for individuals who possess certain types of hematologic malignancies. In certain instances, such as myelodysplastic syndromes (MDS), a reduction in cells for cultivation is encountered, while in other cases, such as chronic myeloid leukemia (CML) or acute myeloid leukemia (AML), a substantial increase in these cells is observed. And, in numerous instances, our knowledge of the patient's malignancy remains unknown, and we anticipate arriving at a diagnosis through the analysis of the karyotype. Consequently, it is an erroneous assumption to believe that a specific quantity of cells is consistently present in 100 micro-liters of the sample for BM cultivation, as the success of cell cultivation is wholly reliant on the number of cells introduced into the culture medium for karyotyping. So, cell enumeration represents a pivotal stage in the cultivation of BM samples and cannot be simplistically deduced from it.